Focal boost to residual gross tumor volume in brachytherapy for cervical cancer-A feasibility study

It is possible to boost the prescription dose to the GTV-Tres achieving 140% increase, which equates to an EQD2α/β=10 > 100 Gy. Plans without both interstitial catheters and/or intrauterine within the GTV-Tres are most likely to be suboptimal. This planning study demonstrates that dose escalation to the GTV-Tres is feasible and further work into clinical application should be considered.